Robust, effective treatments for Parkinson’s freezing of gait remain elusive. Our previous study revealed beneficial effects of high-frequency rTMS over the supplementary motor area. The present study aims to explore the neural mechanisms of rTMS treatments utilizing novel exploratory multivariate approaches. We first conducted a resting-state functional MRI study with a group of 40 Parkinson’s disease patients with freezing of gait, 31 without freezing of gait, and 30 normal controls. A subset of 30 patients with freezing of gait (verum group: N = 20; sham group: N = 10) who participated the aforementioned rTMS study underwent another scan after the treatments. Using the baseline scans, the imaging biomarkers for freezing of gait and Parkinson’s disease were developed by contrasting the connectivity profiles of patients with freezing of gait to those without freezing of gait and normal controls, respectively. These two biomarkers were then interrogated to assess the rTMS effects on connectivity patterns. Results showed that the freezing of gait biomarker was negatively correlated with Freezing of Gait Questionnaire score (r = −0.6723, p < 0.0001); while the Parkinson’s disease biomarker was negatively correlated with MDS-UPDRS motor score (r = −0.7281, p < 0.0001). After the rTMS treatment, both the freezing of gait biomarker (0.326 ± 0.125 vs. 0.486 ± 0.193, p = 0.0071) and Parkinson’s disease biomarker (0.313 ± 0.126 vs. 0.379 ± 0.155, p = 0.0378) were significantly improved in the verum group; whereas no significant biomarker changes were found in the sham group. Our findings indicate that high-frequency rTMS over the supplementary motor area confers the beneficial effect jointly through normalizing abnormal brain functional connectivity patterns specifically associated with freezing of gait, in addition to normalizing overall disrupted connectivity patterns seen in Parkinson’s disease.

INTRODUCTION

Freezing of gait (FOG), characterized by sudden and brief episodes of inability to produce effective forward stepping, is one of the most common and debilitating symptoms in Parkinson’s disease (PD). It is a major risk factor for falls and contributes greatly to reduced mobility and quality of life. Treatment of FOG is very challenging, as evidence for pharmacological treatment, deep brain stimulation, and rehabilitation strategies is inconclusive. Repetitive transcranial magnetic stimulation (rTMS), a noninvasive neural modulation technique, has been used as a treatment for various neurologic and psychiatric disorders. A recent meta-analysis carried out by Wagle et al. demonstrated that rTMS therapy improves general motor symptoms and can be used as a potential adjunct therapy for PD patients. However, it is suggested that future studies are warranted to specifically examine rTMS effects on particular clinical features of PD, including FOG.

There is increasing evidence suggesting that supplementary motor area (SMA) plays an important role in the pathogenesis of FOG, and may be a potential rTMS treatment target. In our previous study, we therefore investigated the clinical efficiency of high-frequency rTMS over SMA on FOG in PD patients. The detailed protocol can be found in our previous publication. Briefly, we performed a randomized, double-blind, sham-controlled experiment with a parallel design consisting of two arms: 10-Hz rTMS over SMA and sham stimulation. Thirty eligible and willing PD-FOG subjects were randomly assigned (with a 2:1 ratio) into two groups with sealed envelopes, to receive either a verum (N = 20) or sham (N = 10) rTMS protocol. Verum or sham rTMS over SMA were carried out in 10 sessions over two successive weeks, one session per day for 5 consecutive days per week. A 7-cm, handheld, figure-of-8 coil was connected to a biphasic magnetic stimulator (Magstim Rapid; The Magstim Co. Ltd., UK). In each session, a 5-s burst of 10-Hz rTMS was repeated every minute for 20 times (in total, 1000 pulses, 20 min duration). Medication was kept constant throughout the trial, all interventions and assessments were carried out in the “ON” state at approximately the same time of day. The improvement of FOGQ score was used as the primary clinical outcome; with MDS-UPDRS III and a Timed Up-and-Go (TUG) test as secondary clinical outcomes. With a 4-week’s follow-up, our results revealed a significantly decreased FOGQ score, significant improvements of MDS-UPDRS III and gait variables in the verum group; whereas no significant improvements were found in the sham group.

Though our prior study investigated the clinical effects of rTMS therapy on FOG in PD patients, however, the underlying neural mechanisms of rTMS-induced improvements need to be further addressed. Resting-state functional MRI (rs-fMRI) proves valuable in understanding the pathophysiology of some features of PD, ...
including FOG. This non-invasive method infers neural activity from spontaneous blood-oxygen-level-dependent (BOLD) signal fluctuations. Functional connectivity can be inferred from spatially distinct brain regions that show temporally correlated time courses during rest. In this study, we aim to explore the neural mechanisms of rTMS treatments utilizing rs-fMRI techniques. More specifically, in order to establish if rTMS over SMA works on FOG specifically or on PD generally (or both), we applied novel exploratory multivariate approaches to identify the imaging biomarkers for FOG (FOGbm) and PD (PDbm) by contrasting the functional connections in datasets from PD patients with FOG (PD-FOG) to those without FOG (PD-noFOG) and normal controls (NC), respectively. Next, we studied the effects of high-frequency rTMS on the aforementioned two imaging biomarkers. We hypothesized that at least one biomarker would be improved, which would indicate that the abnormal brain connectivity pattern of PD-FOG was normalized or modulated by the utilization of rTMS over SMA.

RESULTS
Participants
The flow of participants is presented in Fig. 1. In the rs-fMRI study, two PD-FOG and one PD-noFOG subjects were excluded in the preprocessing due to the failure of the automatic segmentation and overall poor data quality. Thus rs-fMRI data from 38 PD-FOG, 30 PD-noFOG, and 30 NC were ultimately analyzed. In the rTMS study, the post-rTMS fMRI of three patients in the verum group and one in the sham group were excluded during preprocessing. In addition, there was also one patient from the sham group who could not perform the post-rTMS fMRI scan for personal issues. Therefore, a total of 17 pairs of pre-rTMS and post-rTMS fMRI comparisons in the verum group and 8 pairs in the sham group were finally analyzed.

Participant demographics and clinical features are described in Table 1. Briefly, PD-FOG subjects had longer disease duration, more severe parkinsonism as assessed by H-Y stage and MDS-UPDRS III scores, as well as higher levodopa equivalent daily dose (LED). There were no significant differences in gender, age, and MoCA scores among the three groups. In addition, patients in the verum and sham group had similar baseline characteristics.

rTMS study: clinical efficiency
A more detailed description of the clinical efficiency of rTMS can be found in our previous publication. Briefly, the patients were assessed at baseline (T0), after the 5th (T1) and 10th (T2) sessions, and then 2 weeks (T3) and 4 weeks (T4) after the last session. As shown in Table 3, with a 4 weeks follow-up, our results revealed significant interaction effects between group (verum group and sham group) and time (T0, T1, T2, T3, and T4) in the FOGQ (p = 0.04), MDS-UPDRS III (p = 0.02) and several gait variables (total duration, p < 0.01; cadence, p = 0.04; turn duration, p = 0.01; and turn to sit duration, p = 0.02). Post-hoc analyses showed that in the verum group, FOGQ score was significantly decreased at T2 and T4, while MDS-UPDRS III and gait variables were significantly improved at T1, T2, T3, and T4. However, no significant improvements were found in the sham group. Regarding the adverse effects, three subjects in the verum group and one subject in the sham group reported mild but tolerable headache.

Rs-fMRI study: FOGbm and PDbm identification
The PCfdr method detected 160 significant connections between the selected ROIs, representing ~6.5% of all possible 50 × 49 = 2450 directional connections. When computing the FOGbm and PDbm, 20 and 12 out of these 160 functional connections, respectively, survived after the LASSO regression operator. Therefore, a total of 17 pairs of pre-rTMS and post-rTMS fMRI comparisons in the verum group and 8 pairs in the sham group were finally analyzed.

Participant demographics and clinical features are described in Table 1. Briefly, PD-FOG subjects had longer disease duration,
of 86.0% and negative predictive value of 96.0%. Mean FOGbm of PD-FOG was significantly smaller than PD-noFOG (0.316 ± 0.127 vs. 0.600 ± 0.153, \( p < 0.0001 \)) (Fig. 3a). Correlation analysis between FOGbm and FOGQ scores showed a significantly negative correlation (\( r = -0.6723, p < 0.0001 \)) (Fig. 3b).

Ninety-two percent (35/38) PD-FOG and 16.7% (5/30) NC were considered as PD+ (\( \chi^2, p < 0.0001 \)) by PDbm, giving a sensitivity of 92.1%, specificity of 83.3%, positive predictive value of 87.5% and negative predictive value of 89.3%. PD-FOG had smaller mean PDbm than NC (0.315 ± 0.117 vs. 0.587 ± 0.114, \( p < 0.0001 \)) (Fig. 3c). Also, there was a negative correlation between PDbm and MDS-UPDRS III scores (\( r = -0.7281, p < 0.0001 \)) (Fig. 3d).

rTMS study: FOGbm and PDbm comparison
At baseline, the verum and sham groups had similar values of FOGbm (0.326 ± 0.125 vs. 0.333 ± 0.176, \( p = 0.9171 \)), as well as similar PDbm (0.313 ± 0.126 vs. 0.313 ± 0.105, \( p = 0.9986 \)) before stimulation. All 17 patients in the verum group and 87.5% (7/8) patients in the sham group were identified as FOG+ using FOGbm. Ninety-four percent (16/17) patients in the verum group were identified as PDbm+ using PDbm.

Table 1. Demographic and clinical features of participants.

| Variables                      | rs-fMRI study                  | \( p \)  | rTMS study                  | \( p \)  |
|--------------------------------|--------------------------------|---------|----------------------------|---------|
|                                | PD-FOG (N = 40)                | PD-noFOG (N = 31) | NC (N = 30)                | verum rTMS (N = 20) | sham rTMS (N = 10) |
| Gender (female/male)           | 20/20                          | 11/20   | 16/14                      | 0.4530   | 11/9                    | 5/5                | 0.7958                |
| Age (years)                    | 62.03 ± 9.17                   | 58.03 ± 9.78 | 58.30 ± 7.46               | 0.1075   | 62.65 ± 10.56           | 65.60 ± 8.68       | 0.4241                |
| Disease duration (years)       | 8.18 ± 5.07                    | 5.23 ± 3.46 | –                          | 0.0049*  | 9.15 ± 5.82            | 7.40 ± 4.83        | 0.3932                |
| Onset side (B/R/L)             | 7/21/12                        | 3/19/9  | –                          | 0.6054   | 3/12/5                  | 2/7/1              | 0.6203                |
| H-Y stage                      | 2.58 ± 0.78                    | 1.90 ± 0.61 | –                          | 0.0001*  | 2.60 ± 0.85            | 2.35 ± 0.91        | 0.4802                |
| MDS-UPDRS III (OFF)            | 42.23 ± 18.56                  | 30.81 ± 14.41 | –                          | 0.0047*  | –                      | –                  | –                     |
| MDS-UPDRS III (ON)             | –                              | –       | –                          | 0.0007*  | 759.5 ± 458.4          | 637.2 ± 434.3      | 0.4838                |
| LEDD (mg/d)                    | 698.8 ± 398.3                  | 398.3 ± 291.3 | –                          | –        | 34.15 ± 13.60          | 35.30 ± 16.71      | 0.8529                |
| FOG subtype (OFF/ON freezer)   | 29/11                          | –       | –                          | –        | 15/5                   | 7/3                | 0.7703                |
| FOGQ                           | 16.00 ± 4.64                   | 2.45 ± 1.73 | –                          | <0.0001* | 15.85 ± 4.87          | 14.70 ± 4.03       | 0.4999                |
| MoCA                           | 25.18 ± 3.90                   | 25.13 ± 3.51 | 26.13 ± 3.52               | 0.4749   | 25.10 ± 4.61           | 25.50 ± 4.35       | 0.8185                |

Means and SD are shown for continuous variables.

FOG freezing of gait, Onset side (B/R/L) bilateral/right/left onset, H-Y stage Hoehn and Yahr stage, MDS-UPDRS III Movement Disorder Society-Unified Parkinson’s Disease Rating Scale motor score, FOGQ freezing of gait questionnaire, LEDD levodopa equivalent daily dose, MoCA Montreal Cognitive Assessment.

* \( p < 0.01 \).
and all of the eight patients in the sham group were identified as PD+ using PDbm.

After verum stimulation, both FOGbm (0.326 ± 0.125 vs. 0.486 ± 0.193, p = 0.0071) and PDbm (0.313 ± 0.126 vs. 0.379 ± 0.155, p = 0.0378) were significantly increased (Fig. 4a-left and b-left). However, neither of these two biomarkers showed significant differences after sham stimulation (0.333 ± 0.176 vs. 0.409 ± 0.176, p = 0.1117; 0.313 ± 0.105 vs. 0.328 ± 0.112, p = 0.3518) (Fig. 4a-right and b-right). LASSO regression showed that the greater improvement in FOGbm could be predicted by shorter disease duration and less LEDD, as well as greater improvements in MDS-UPDRS III and turn duration; in contrast, no clinical scores could predict the difference of PDbm.

Qualitatively, six patients considered as FOG+ at baseline were converted into the FOG− group after verum stimulation (McNemar’s test, p = 0.4795). The “transferred” and “non-transferred” patients in the verum group had similar clinical features except that the transferred subjects had shorter disease duration (6.33 ± 3.39 vs. 11.00 ± 6.51 years, p = 0.0355) as well as lower MDS-UPDRS III scores (23.50 ± 7.63 vs. 33.90 ± 12.18 points, p = 0.0479). There were four patients in the verum group (McNemar’s test, p = 0.1336), as well as one in the sham group (McNemar’s test, p = 1.000) that moved from the PD+ to the PD− group after stimulation, but neither of these were statistically significant.

**DISCUSSION**

The present study is the first to explore the underlying brain connectivity mechanisms in supporting the potential treatment effects of rTMS on FOG utilizing rs-fMRI. To this end, we carried out a rs-fMRI study and developed two imaging biomarkers, FOGbm and PDbm, which were negatively correlated with the severity of FOG and motor symptoms, respectively, suggesting that they could be used as biomarkers to assess the effects of rTMS on connectivity patterns. In the subsequent rTMS study, our results revealed significantly increased FOGbm and PDbm after verum stimulation, demonstrating that high-frequency rTMS over SMA not only improves the brain connectivity pattern specifically associated with FOG but also the pattern associated with PD overall. These results therefore suggest that high-frequency rTMS over SMA could alleviate FOG via normalization of abnormal brain connectivity patterns.

We found an imaging biomarker (FOGbm) that contributes to our understanding of the physiopathological basis of FOG. Functional imaging techniques have previously demonstrated that during “motor arrests”, PD-FOG has decreased neural activity within the bilateral sensorimotor regions and a concomitant increased response within the frontal-parietal cortical regions. Another rs-fMRI study demonstrated that functional connectivity disruption of the “fronto-parietal” network is associated with the development of FOG in PD patients. Decreased neural responses have also been observed in a number of subcortical nuclei within the frontostriatal loops during FOG episodes, including the bilateral caudate head, thalamus, subthalamic nucleus, and globus pallidus internus. A re-organization of functional communication within the locomotor network, including the SMA, subthalamic nucleus, mesencephalic, and cerebellar locomotor region, has also been demonstrated in PD-FOG. Taken together, what emerges from these studies is that frontoparietal and frontostriatal dysfunction, as well as neural alterations within the locomotor network, may all take part in the pathophysiology of FOG. In the present study, we selected the union of all these brain regions as our ROIs.

We identified 20 functional connections between brain regions where the connection strengths significantly predicted PD-FOG from PD-noFOG (FOGbm). Consistent with what has been previously described, our results also demonstrated altered functional connectivity within frontoparietal and sensorimotor regions. The increased connectivity from the pallidum to the PPN
in PD-FOG subjects that we observed is in accordance with the “interference model” of FOG, which proposes that FOG is triggered by a paroxysmal excessive inhibition of PPN induced by increased inhibitory outputs originating from the pallidum. In addition, we observed that PD-FOG subjects also had increased connectivity strengths within the superior temporal gyrus and insula. The superior temporal gyrus is closely linked with the connectivity strengths within the superior temporal gyrus and addition, we observed that PD-FOG subjects also had increased inhibitory outputs originating from the pallidum. In triggered by a paroxysmal excessive inhibition of PPN induced by increased inhibitory outputs originating from the pallidum. In addition, we observed that PD-FOG subjects also had increased inhibitory outputs originating from the pallidum. In

Several mechanisms could explain the favorable effect of rTMS on PD-FOG. First, the FOGbm, which represents the specific abnormal brain connectivity pattern in PD-FOG from those without FOG, is significantly improved after verum stimulation, but not sham stimulation. Moreover, this difference was correlated with clinical improvements. These results suggest that rTMS over SMA changes the brain connectivity pattern of PD-FOG towards the pattern of PD-noFOG, in other words, it, at least partly, works on normalizing disrupted connectivity patterns seen in FOG specifically. Previous animal 6,27 and human 28,29 studies have revealed that rTMS over cortex can confer effects on remote subcortical regions. Therefore, we assume that the beneficial effect of rTMS over SMA may attribute to its modulation on the brain connectivity evolving other remotely connected brain regions. However, given the fact that rTMS induces neuronal excitability, we cannot totally rule out the possibility that it might also work through the facilitation of the underactivated neurons of SMA. Further analyses regarding the specific brain activity changes of SMA after rTMS is warranted. We found that those patients who transferred from FOG+ to FOG− after verum stimulation had shorter disease duration than those did not, and FOGbm difference could be predicted with shorter disease duration. These results suggest that patients may benefit more from rTMS at earlier stages of the disease. Similarly, the PDbm was also significantly increased after stimulation in the verum group, but not in the sham group. Together with the improvement in MDS-UPDRS III scores, as mentioned above, we propose that rTMS over SMA could also influence overall brain connectivity patterns indicative of PD. In addition, we noticed that there were two patients moved from the FOG+ to FOG− group, as well as one patient moved from the PD+ to PD− group after sham stimulation. This could be attributed to the placebo effect in PD, which is mediated through substantial release of endogenous dopamine in the striatum, thereby improving general PD symptomatology. We note that although FOG becomes more dopa-resistant with disease progression, it is generally l-dopa responsive in early stages. Thus the dopa-mediated placebo effect may improve FOG symptomatology in early stage patients. In conclusion, we speculate that rTMS over SMA confers not only a direct therapeutic effect but also a placebo effect, both of which can improve abnormal brain connectivity patterns of PD-FOG.

In this study, we utilized the exploratory multivariate approaches instead of looking at each single feature to identify the specific brain connectivity pattern. As the brain is one of the most complex systems, single connectivity changes may be inadequate to represent the whole brain functioning. Current results further indicate that rTMS has wide impacts over the whole brain connectivity which demonstrates the importance in studying the whole brain connectivity patterns using novel exploratory multivariate approaches.

In conclusion, our results suggest that high-frequency rTMS over SMA confers the beneficial effect by normalizing the abnormal brain functional connectivity pattern of PD-FOG and makes it not only more similar to those without FOG, but also more similar to NC. This study provides powerful evidence of high-frequency rTMS over SMA serving as an add-on therapy for alleviating FOG in PD patients.

METHODS
Participants
The experiments were performed according to the Declaration of Helsinki and were approved by the Institutional Review Board of Xuanwu Hospital of Capital Medical University. Written informed consent was obtained from all participants prior to the study. Patients diagnosed with idiopathic PD according to the UK Brain Bank Clinical Criteria were recruited from the
Movement Disorders Clinic of the Xuanwu Hospital between August 2015 and December 2017. Exclusion criteria were: (i) presence of contra-indications for rs-fMRI or rTMS; (ii) history of deep brain stimulation surgery; (iii) marked rest tremor; (iv) comorbidities of neurological disease other than PD; (v) history of receiving any kinds of rTMS; and (vi) left-handedness. FOG subjects were identified by three criteria as described in our previous study. In addition, a control group of sex-matched and age-matched healthy volunteers were recruited from the local community or from patients’ relatives. The study was registered at the Clinical Trial Registration (http://www.clinicaltrials.gov, unique identifier: NCT03219982).

According to the above criteria, we recruited 40 PD-FOG, 31 PD-noFOG, and 30 NC for the rs-fMRI study to identify the imaging biomarkers, and then invited the PD-FOG subjects to participate in the aforementioned rTMS study. Thirty out of the 40 PD-FOG from the primary group agreed to participate in the rTMS study. All of the PD-FOG subjects enrolled in the study were either OFF freezers (freezing occurs predominantly or even exclusively in the OFF-state) or OFF/ON freezers (dopamine-resistant and no difference between ON and OFF-state), the identification of which were based on patients’ usual medication. The demographic and clinical characteristics of the participants are shown in Table 1.

Rs-fMRI study: clinical assessments
For all the PD patients, clinical assessments were evaluated during their practical “OFF” state (withdrawal of anti-Parkinson medications for at least 12 h), including the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale motor scores (MDS-UPDRS III), Hoehn and Yahr (H–Y) stage, FOG Questionnaire (FOGQ), and Montreal Cognitive Assessment (MoCA).

Rs-fMRI study: rs-fMRI data acquisition
Imaging was carried out in a SIEMENS Trio 3 T scanner. Participants were instructed to keep their head still and eyes closed during scanning, but not fall asleep. Earplugs and a head coil with foam pads were used to minimize machine noise and head motion. For PD patients, rs-fMRI scans were acquired following a 12-hour period of medication withdrawal. Note that the data of the 30 PD-FOG subjects who were also enrolled in the rTMS study were used as pre-rTMS rs-fMRI. For each participant, we also acquired high-resolution T1-weighted anatomical images, and a radiologist assessed the images to exclude participants with space-occupying lesions, stroke, or other pathology. Structural images were acquired using a sagittal magnetization prepared rapid gradient echo three-dimensional T1-weighted sequence (repetition time [TR] = 1970 ms, echo time [TE] = 3.9 ms, inversion time [TI] = 1100 ms, flip angle [FA] = 15°). BOLD images were obtained using the following SE-EPI sequence: repetition time = 2000 ms, echo time = 30 ms, slice thickness/gap = 4.0/0 mm, axial slices = 33 layers, flip angle = 90°, FOV = 256 mm × 256 mm, matrix size = 64 × 64, and scanning time = 8 min.

Rs-fMRI study: rs-fMRI data preprocessing
The acquired rs-fMRI data were preprocessed using the AFNI software package. Several pre-processing steps were performed, including despiking, slice timing correction, and 3D isotropic reslicing. Any head motion during the scan was removed by performing a rigid body alignment. The corresponding T1 scans were used to automatically segment the brain into different regions of interest (ROIs) using FreeSurfer. Each of the subject structural scan was then registered using rigid registration to the corresponding subject’s fMRI scan. The ROI masks thus obtained in T1 space from FreeSurfer were then projected onto the fMRI space. All the subsequent analyses were done in the individual native space rather than in a common template space to prevent introducing any unwanted distortions in the fMRI data by registration to a common template. Next, several sources of variance such as head-motion parameters, their temporal derivatives, squares of the temporal derivatives, white-matter signal, and CSF-signal were removed using regression. The white-matter and CSF-signal confounding timeseries were obtained by averaging over the voxels segmented and labeled as white-matter and CSF, respectively. All functional images were resampled into 3.0 × 3.0 × 3.0 mm^3 resolution. The obtained fMRI signal was then detrended to remove any linear and quadratic trends from the signal. After detrending, the signal was spatially smoothed using 6 × 6 × 6 FWHM and finally, it was bandpass filtered between 0.01 and 0.08 Hz as has been previously suggested for rs-fMRI studies.

Rs-fMRI study: connectivity analysis (PCfdr-DBN)
As shown in Table 2, we selected 50 ROIs based on regions involved in the fronto-parietal network, the frontostriatal loop, and the locomotor network, all of which have been previously studied and proven to be associated with FOG in PD. All of the ROIs except the bilateral pedunculopontine (PPN) were automatically segmented by FreeSurfer. Locating the fMRI signals from the PPN required special consideration. The PPN is an elongated neuronal collection in the lateral pontine and mesencephalic tegmental reticular zones. Its long axis roughly parallels to the long axis of the floor of the fourth ventricle, with the nucleus straddling the pontomesencephalic junction extending ~5 mm from the mid-inferior collicular level to reach the rostral pons. Due to the limitation of fMRI spatial resolution and the small size of the PPN, any mis-position of PPN area may produce the misleading results in connectivity estimation. As the fMRI signals have been spatially smoothed, here in this study, we included a relatively large number of voxels to represent PPN areas. We first started with the midbrain and pontine FreeSurfer labels. At the midbrain/pons junction we divided the anterior–posterior direction of the midbrain into three equal parts. The central partition area, containing the area between the medial lemniscus and superior cerebellar peduncle, was assumed to contain the PPN. We averaged these voxels within this partition to get the PPN signal.

The connectivity network between ROIs was first computed with a PCfdr algorithm using mean time courses of selected ROIs. The PC algorithm is an efficient Bayesian learning approach that infers the interactions between variables (in this case, mean voxel values within ROIs) by detecting the conditional dependence/independence relationships between them. An extension of the PC algorithm, the PCfdr algorithm, controlling the type I error rate individually for each connection and integrates a false discovery rate control procedure into the network.

Table 2. The 50 ROIs used in the connectivity analysis.

| No. Brain regions | No. Brain regions |
|-------------------|-------------------|
| ctx_lh_G_parcenctal| ctx_rh_G_parcenctal|
| ctx_lh_G_parcenctal| ctx_rh_G_parcenctal|
| ctx_lh_G_front_middle| ctx_rh_G_front_middle|
| ctx_lh_G_pariet_inf-Angular| ctx_rh_G_pariet_inf-Angular|
| ctx_lh_G_pariet_inf-Supramar| ctx_rh_G_pariet_inf-Supramar|
| ctx_lh_G_parietal_sup| ctx_rh_G_parietal_sup|
| Left-caudate| Right-caudate|
| Left-putamen| Right-putamen|
| Left-pallidium| Right-pallidium|
| Left-thalamus-proper| Right-thalamus-proper|
| Left-cerebellum-cortex| Right-cerebellum-cortex|
| ctx_lh_insula| ctx_rh_insula|
| ctx_lh_G_temp_sup-G_T_transv| ctx_rh_G_temp_sup-G_T_transv|
| ctx_lh_G_temp_sup-Lateral| ctx_rh_G_temp_sup-Lateral|
| ctx_lh_G_temp_sup-Plan_polar| ctx_rh_G_temp_sup-Plan_polar|
| ctx_lh_G_temp_sup-Plan_tempo| ctx_rh_G_temp_sup-Plan_tempo|
| ctx_lh_G_cingul-Ant| ctx_rh_G_cingul-Ant|
| ctx_lh_G_cingul-Post-dorsal| ctx_rh_G_cingul-Post-dorsal|
| ctx_lh_G_cingul-Post-ventral| ctx_rh_G_cingul-Post-ventral|
| ctx_lh_G_preccuneus| ctx_rh_G_preccuneus|
| Left-PMD| Right-PMD|
| Left-PMV| Right-PMV|
| Left-SMA| Right-SMA|
| Left-pre-SMA| Right-pre-SMA|
| Left-PPN| Right-PPN|
learning, is suitable for brain connectivity assessment. The results of applying the PCdf algorithm is a binary undirected connectivity network which embeds the conditional independence relationships into the skeleton of a graph. To further estimate the connectivity directions and strengths, a dynamic Bayesian network (DBN) learning method was then adopted. We chose DBN modeling as it has a solid basis in statistics and easily incorporates the prior domain knowledge. The directionality was estimated according to the maximum likelihood criterion. In this study, all the subjects were used to estimate the structures and directions. Then the coefficients were estimated individually for each subject. As stated previously by Li et al., when performing group level analysis using DBN for functional connectivity interpretations, there are three generally used approaches: assuming a “virtual-typical subject” that learns a common network (both directionality and coefficients) for all the subjects from different groups; a “individual-structure” approach that learns the individual network for each subject separately; and a “common-structure” approach that imposes the same structure (and directionality), but allows the strength of the connections to vary between different groups.

Table 3. Clinical efficiency of the verum and sham rTMS.

|                | Verum group | Sham group | f   | p    |
|----------------|-------------|------------|-----|------|
| FOGQ           |             |            |     |      |
| T0             | 16.04 ± 0.82| 16.00 ± 1.84| 0.34| 0.56 |
| T1             | 14.44 ± 0.82| 15.40 ± 1.83| 3.04| 0.06 |
| T2             | 13.91 ± 0.84| 16.40 ± 1.84| 3.57| 0.04*|
| MDS-UPDRS III  |             |            |     |      |
| T0             | 34.75 ± 3.08| 35.40 ± 4.36| 0.62| 0.44 |
| T1             | 31.75 ± 3.08| 35.10 ± 4.36| 7.12| <0.01*|
| T2             | 29.55 ± 3.08| 34.60 ± 4.36| 3.15| 0.02*|
| T3             | 28.06 ± 3.10| 33.41 ± 4.37|     |      |
| T4             | 28.96 ± 3.11| 35.16 ± 4.39|     |      |

Gait analyses

|                | Group | Time | Group × time | p    |
|----------------|-------|------|--------------|------|
| Total duration (s) | 62.15 ± 2.16 | 27.34 ± 3.06 | 1.44 | 0.24 |
| Cadence (steps/min) | 23.11 ± 2.16 | 28.45 ± 3.07 | 1.41 | 0.23 |
| Turn: Duration (s) | 23.61 ± 2.17 | 28.13 ± 3.06 | 4.97 | <0.01*|
| Turn to Sit (s) | 24.24 ± 2.19 | 29.46 ± 3.08 | 2.68 | 0.04*|

Means and SD are shown for continuous variables.

Table 4. The individual directional connections within the selected network found to significantly predict FOGbm and PDbm.

| From          | To                | Sign* |
|---------------|-------------------|-------|
| FOGBm         |                   |       |
| 1             | ctx_lh_G_temp_sup |       |
| 2             | ctx_lh_G_temp_sup |       |
| 3             | ctx_lh_G_temp_sup |       |
| 4             | ctx_lh_G_temp_sup |       |
| 5             | ctx_lh_G_temp_sup |       |
| 6             | ctx_lh_G_temp_sup |       |
| 7             | ctx_lh_G_temp_sup |       |
| 8             | ctx_lh_G_temp_sup |       |
| 9             | ctx_lh_G_temp_sup |       |
| 10            | ctx_lh_G_temp_sup |       |
| 11            | ctx_lh_G_temp_sup |       |
| 12            | ctx_lh_G_temp_sup |       |
| 13            | ctx_lh_G_temp_sup |       |
| 14            | ctx_lh_G_temp_sup |       |
| 15            | ctx_lh_G_temp_sup |       |
| 16            | ctx_lh_G_temp_sup |       |
| 17            | ctx_lh_G_temp_sup |       |
| 18            | ctx_lh_G_temp_sup |       |
| 19            | ctx_lh_G_temp_sup |       |
| 20            | ctx_lh_G_temp_sup |       |
| 21            | ctx_lh_G_temp_sup |       |
| 22            | ctx_lh_G_temp_sup |       |
| 23            | ctx_lh_G_temp_sup |       |
| 24            | ctx_lh_G_temp_sup |       |
| 25            | ctx_lh_G_temp_sup |       |
| 26            | ctx_lh_G_temp_sup |       |
| 27            | ctx_lh_G_temp_sup |       |
| 28            | ctx_lh_G_temp_sup |       |
| 29            | ctx_lh_G_temp_sup |       |
| 30            | ctx_lh_G_temp_sup |       |
| 31            | ctx_lh_G_temp_sup |       |
| 32            | ctx_lh_G_temp_sup |       |
| 33            | ctx_lh_G_temp_sup |       |
| 34            | ctx_lh_G_temp_sup |       |
| 35            | ctx_lh_G_temp_sup |       |
| 36            | ctx_lh_G_temp_sup |       |
| 37            | ctx_lh_G_temp_sup |       |
| 38            | ctx_lh_G_temp_sup |       |
| 39            | ctx_lh_G_temp_sup |       |
| 40            | ctx_lh_G_temp_sup |       |
| 41            | ctx_lh_G_temp_sup |       |
| 42            | ctx_lh_G_temp_sup |       |
| 43            | ctx_lh_G_temp_sup |       |
| 44            | ctx_lh_G_temp_sup |       |
| 45            | ctx_lh_G_temp_sup |       |
| 46            | ctx_lh_G_temp_sup |       |
| 47            | ctx_lh_G_temp_sup |       |
| 48            | ctx_lh_G_temp_sup |       |
| 49            | ctx_lh_G_temp_sup |       |
| 50            | ctx_lh_G_temp_sup |       |
| 51            | ctx_lh_G_temp_sup |       |
| 52            | ctx_lh_G_temp_sup |       |
| 53            | ctx_lh_G_temp_sup |       |
| 54            | ctx_lh_G_temp_sup |       |
| 55            | ctx_lh_G_temp_sup |       |
| 56            | ctx_lh_G_temp_sup |       |
| 57            | ctx_lh_G_temp_sup |       |
| 58            | ctx_lh_G_temp_sup |       |
| 59            | ctx_lh_G_temp_sup |       |
| 60            | ctx_lh_G_temp_sup |       |

The individual directional connections within the selected network found to significantly predict FOGbm and PDbm.

To identify the FOGbm and PDbm, a logistic least absolute shrinkage and selection operator (LASSO) regression with leave-one-out cross-validation method was adopted. The strengths of the detected connections were used as independent variables, and group labels (labeled FOG and PD -- as 0 and 1 for FOGbm; labeled PD+ and PD-- as 0 and 1 for PDBm) were treated as the response variables in the regression model. The logistic LASSO would optimally distinguish groups and select the important connectivity features in classification (the features with non-zero regression coefficients). As a result, we could compute the estimated group label as the biomarker for FOG (FOGbm) and PD (PDBm), respectively. When computing the FOGbm, we included MDS-UPDRS III scores as a covariate to minimize any effects of disease severity. By contrasting PD-FOG to PD-noFOG, with a threshold of 0.5, a value of FOGbm ranging from 0 to 0.5 was considered as belonging to FOG+, while a value ranging from 0.5 and 1.0 was considered as belonging to FOG−. Similarly, by comparing PD-FOG with NC, PDbm was computed to give the probability of the subject belonging to the PD+ (range from 0 to 0.5) or PD− (range from 0.5 to 1.0) group. Correlations between the biomarkers and clinical scores were also analyzed.

rTMS study: FOGbm and PDbm comparison

A post-rTMS fMRI scan was acquired 1 or 2 days after the last session of rTMS. The acquisition paradigm, preprocessing and processing methods were same as used in the prior rs-fMRI study. The FOGbm and PDbm...
generated in the rs-fMRI study were compared between pre-rTMS and post-rTMS to assess the effects of rTMS on the FOG-related and PD-related brain connectivity patterns in PD-FOG patients, respectively.

Statistics analysis
Demographic data were presented as mean ± SD for continuous variables. Independent two-sided t-test was performed for the comparison of continuous variables, and the χ² test was used to compare categorical variables. Two-sided paired t-test and McNemar's test were used to test the biomarker changes before and after rTMS. The threshold for the level of significance was set at α = 0.05. All statistical analyses were performed using JMP Pro 12.0 software (SAS Institute Inc., NC). Graphics were created using Prism 7.0.

DATA AVAILABILITY
The datasets generated during and/or analyzed during the current study are available from the corresponding authors on reasonable request.

Received: 18 January 2020; Accepted: 15 June 2020; Published online: 17 July 2020

REFERENCES
1. Nutt, J. G. et al. Freezing of gait: moving forward on a mysterious clinical phenomenon. Lancet Neurol. 10, 734–744 (2011).
2. Nonnikes, J. et al. Freezing of gait: a practical approach to management. Lancet Neurol. 14, 768–778 (2015).
3. Wassermann, E. M. & Lisanby, S. H. Therapeutic application of repetitive transcranial magnetic stimulation: a review. Clin. Neurophysiol. 112, 1367–1377 (2001).
4. Wagle Shukla, A. et al. Repetitive Transcranial Magnetic Stimulation (rTMS) therapy in Parkinson disease: a meta-analysis. PM R. 8, 356–366 (2016).
5. Snijders, A. H. et al. Gait-related cerebral alterations in patients with Parkinson’s disease with freezing of gait. Brain 134, 59–72 (2011).
6. Peterson, D. S., Pickett, K. A., Duncan, R., Perlmutter, J. & Earhart, G. M. Gait-related brain activity in people with Parkinson disease with freezing of gait. PLoS ONE 9, e90634 (2014).
7. Shine, J. M. et al. Differential neural activation patterns in patients with Parkinson’s disease and freezing of gait in response to concurrent cognitive and motor load. PLoS ONE 8, e52602 (2013).
8. Mi, T.-M. et al. High-frequency rTMS over the supplementary motor area improves freezing of gait in Parkinson’s disease: a randomized controlled trial. Parkinsonism Relat. Disord. 68, 85–90 (2019).
9. Wu, T. et al. Functional connectivity of cortical motor areas in the resting state in Parkinson’s disease. Hum. Brain Mapp. 32, 1443–1457 (2011).
10. Gao, L. L. & Wu, T. The study of brain functional connectivity in Parkinson’s disease. Transl. Neurodegener. 5, 18 (2016).
11. Kahan, J. et al. Resting state functional MRI in Parkinson’s disease: the impact of deep brain stimulation on ‘effective’ connectivity. Brain 137, 1130–1144 (2014).
12. Mantini, D., Perrucci, M. G., Del Gratta, C., Romani, G. L. & Corbetta, M. Electro-physiological signatures of resting state networks in the human brain. Proc. Natl. Acad. Sci. USA 104, 13170–13175 (2007).
13. Horn, A., Ostwald, D., Reisert, M. & Blankenburg, F. The structural-functional connectome and the default mode network of the human brain. Neuroimage 102 (Part 1), 142–151 (2014).
14. van den Heuvel, M. P. & Hulshoff Pol, H. E. Exploring the brain network: a review on resting-state fMRI functional connectivity. Eur. Neuropsychopharmacol. 20, 519–534 (2010).
15. Shine, J. M. et al. Exploring the cortical and subcortical functional magnetic resonance imaging changes associated with freezing in Parkinson’s disease. Brain 136, 1204–1215 (2013).
16. Tessitore, A. et al. Resting-state brain connectivity in patients with Parkinson’s disease and freezing of gait. Parkinsonism Relat. Disord. 18, 781–787 (2012).
17. Fling, B. W. et al. Functional reorganization of the locomotor network in Parkinson patients with freezing of gait. PLoS ONE 9, e100291 (2014).
18. Lewis, S. J. & Barker, R. A. A pathophysiological model of freezing of gait in Parkinson’s disease. Parkinsonism Relat. Disord. 15, 333–338 (2009).
19. Del Casale, A. et al. Functional neuroimaging in psychosis. Neuropsychobiology 72, 97–117 (2013).
20. Bowers, D. et al. Startling facts about emotion in Parkinson’s disease: blunted reactivity to aversive stimuli. Brain 129, 3356–3365 (2006).

ACKNOWLEDGEMENTS
This work was supported by the grants from the National Key R&D Program of China (No. 2018YFC1312001, 2017YFC0804105, and 2017YFC1310200), Beijing Municipal Administration of Hospitals’ Mission Plan (SML20150803), Beijing Municipal Science & Technology Commission (Z171100001171103), National Natural Science Foundation of China (61473196), Beijing Talents Foundation (2016000021233D07), M.J.M. is supported by the UBC/PPRI Chair in Parkinson’s Disease Research.

AUTHOR CONTRIBUTIONS
P.C. and K.-C.L. designed the study; T.-M.M., L.-L.G., P.-P.L., Q.J., and E.-H.X. carried out data collection; M.J.M., S.G., and A.P.L. analyzed the rs-fMRI data; T.-M.M. analyzed the clinical data; T.-M.M., S.G., and A.P.L. drafted the manuscript; M.J.M., P.C., and F.B. revised the manuscript. All authors read and approved the final version for publication.

COMPETING INTERESTS
The authors declare no competing interests.

npj Parkinson’s Disease (2020) 16
Published in partnership with the Parkinson’s Foundation
ADDITIONAL INFORMATION

Supplementary information is available for this paper at https://doi.org/10.1038/s41531-020-0118-0.

Correspondence and requests for materials should be addressed to A.-P.L., K.-C.L. or P.C.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.